CLAIMS

1. Use of an elemental gold nanosuspension in the manufacture of a medicament for the treatment of a disease selected from the group consisting of Progressive Supranuclear Palsy, Alexander's Disease, Krabbe Disease, Metachromatic Leukodystrophy, Canvan Disease, Leukodistrophies, Central Pontine Myelolysis (CPM), Anti-MAG Disease, Pelizaeus-Merzbacher Disease, Refsum Disease, Cockayne Syndrome, Zellweger Syndrome, Guillain-Barre Syndrome (GBS), Van der Knapp Syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), Neuromyelitis Optica (NMO), Progressive Multifocal Leukoencephalopathy (PML), Mild Cognitive Impairment (MCI), Wallerian Degeneration, and Adrenoleukodystrophy.

2. The use according to Claim 1, wherein said disease comprises Neuromyelitis Optica (NMO).

3. The use according to Claim 1 or Claim 2, wherein said elemental gold nanosuspension comprises:

a.) pharmaceutical grade water;

b.) at least one processing enhancer, selected from the group consisting of: a carbonate, a sodium or potassium phosphate, a sulfite, and a bisulfite; and

c.) gold nanocrystals suspended in said water forming a suspension, wherein said gold nanocrystals:

i.) have surfaces that include at least one characteristic selected from the group of characteristics consisting of: (1) no organic chemical constituents adhered or attached to said surfaces and/or (2) are substantially clean and do not have chemical constituents adhered or attached to surfaces, other than water or said processing enhancer, which alter the functioning of said nanocrystals;

ii.) have a mode particle size of less than 50nm;

iii.) are present in said suspension at a concentration of 2-2000ppm;

wherein said suspension has a pH of between 5 to 9.5 and a zeta potential of at least -20mv.

4. The use according to Claim 3 wherein said processing enhancer is sodium bicarbonate.

5. The use according to Claim 3 wherein said gold nanocrystals are present in said suspension at a concentration of 2-200ppm.

6. The use according to Claim 3 wherein said nanosuspension has a zeta potential of at least -30 mV.

7. The use according to Claim 6 wherein said nanosuspension has a zeta potential of at least -40 mV.